Non-opioid pain Identify partnerships or licensing opportunities around non-opioid pain therapeutics, especially Nav1.8 inhibitors like LTG-001, to expand portfolio reach or co-development in adjacent pain indications and surgical analgesia.

Clinical-stage momentum Leverage Latigo's clinical-stage status and recent Series B funding to engage in collaboration discussions with contract research organizations, CDMOs, and strategic partners seeking near-term innovation assets in the pain space.

IPO-readiness leverage Target investors, banks, and partnering firms interested in Latigo’s planned IPO trajectory to explore strategic alliances, equity partnerships, or milestone-driven collaborations that align with liquidity timelines.

Nav1.8 leadership Position LTG-001 as a flagship asset for out-licensing or co-development with pharma companies seeking to bolster their non-opioid analgesia portfolios, especially in acute pain and post-surgical settings.

Investors to customers Engage with Blue Owl Capital and other backers as potential distributors or co-development financiers of additional formulations or delivery methods, while also exploring regional manufacturing and supply chain partnerships.